A naukri.com initiative
Bioengineer
3d
128
Image Credit: Bioengineer
Metformin Curbs Dnmt3aR878H HSPC Dominance
- Clonal hematopoiesis, driven by DNMT3A mutations, involves expansion of blood cell clones with selective growth advantages, posing health risks like hematologic malignancies and inflammatory diseases.
- Mutations in DNMT3A, particularly the R882 hotspot, confer competitive fitness to hematopoietic stem cells (HSCs) through enhanced mitochondrial respiratory activity.
- Metformin, an anti-diabetic drug inhibiting mitochondrial respiration, reduces the competitive edge of mutant HSCs by targeting their enhanced metabolic function.
- Treatment with metformin restores aberrant DNA methylation patterns and epigenetic dysregulation in mutant HSPCs, attenuating clonal dominance.
- Metformin's efficacy in reducing the proliferation advantage of DNMT3A-mutant HSPCs demonstrates therapeutic potential in countering clonal hematopoiesis.
- Research extending to human DNMT3A R882H HSPCs validates metformin's ability to diminish their competitive proliferation advantage, hinting at clinical repurposing.
- Targeting mitochondrial metabolism with metformin offers preventive and adjunctive therapy possibilities to mitigate the risk of hematologic cancers and systemic inflammatory diseases.
- Metformin's dual impact on metabolic and epigenetic pathways highlights its potential to reprogram mutant stem cells towards a more normal state, disrupting clonal dominance.
- Clinical feasibility and safety of metformin facilitate its rapid translation into trials for targeting clonal hematopoiesis, underscoring its practical application in oncology.
- Metformin's role in reversing metabolic and epigenetic changes associated with DNMT3A-mutant clonal expansion opens avenues for novel therapeutic strategies in hematology.
- Further clinical studies are essential to assess metformin's efficacy in delaying hematologic malignancies and investigating metabolic dependencies in clonal hematopoiesis driver mutations.
Read Full Article
7 Likes
For uninterrupted reading, download the app